Photo of Gilberto Lopes taken from med.miami.edu
May 27, 2024, 13:04
Gilberto Lopes: Few of the positive trials we have data for in lung cancer from ASCO24
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared a post on X: .
“Alright!
ASCO abstracts are out. Most plenary and oral are LBAs so not out yet. Let’s check a few of the positive trials we have data for in lung cancer.
HARMONi-A – ivonescimab, an anti-PD-1/VEGF bispecific antibody, added to chemo vs chemo alone after EGFR TKI shows clinically relevant improvement in PFS!
322 patients randomized. 85%+ has 3rd gen – HR 0.46 [0.34, 0.62], P < 0.0001. Clearly positive.
New options for treatment are welcome. No OS data yet. Trial from China. Shouldn’t matter. But that has created challenges for approval in the US recently.”
Source: Gilberto Lopes/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 07:45
Dec 21, 2024, 05:54
Dec 21, 2024, 05:42
Dec 21, 2024, 04:55